← Ticker index
ABBV
Ticker
ABBV
AbbVie Inc.
Healthcare
Congressional Trades
141
by 16 members
Ticker disclosure brief
Congressional disclosure records for ABBV
A ticker-first view of recent disclosures, reported ranges, filing lags, party aggregates, federal awards, lobbying records, and source-linked receipts.
Latest receipt
Ro Khanna
BUY · 2026-06-02
Largest range
$50K – $100K
Jefferson Shreve
Longest observed gap
354d
Julia Letlow
Highest 30d vs SPY
23.1%
Ro Khanna
Purchase rows
72
51%
Sale rows
65
46%
Disclosed midpoint
$1.9M
range estimate
Unique Traders
16
members
Disclosure timing method
Observed filing gaps are not notice-date findings
The reporting deadline is the earlier of 30 days after notice or 45 days after the transaction. Public disclosure rows provide transaction and filing dates, but do not establish when a member received notice. PoliWealth therefore marks only transaction-to-filing gaps over 45 days as an apparent delay for review; 31–45 day gaps are not labeled late from transaction date alone.
Party Breakdown
Democrats83 · 59%
Republicans58 · 41%
Federal awards
all →- 2026-01-07$23KDepartment of Veterans AffairsPROSTHETICS:IMPLANT
Lobbying filings
all →- 2026-07-15$0ABBVIE INC.Issues regarding life sciences related matters. Issues regarding life sciences related matters.
- 2026-07-09$60KABBVIE INC.Issues related to the 340B drug discount program. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals.
- 2026-07-07$80KABBVIE INC.International tax issues and pharmaceutical pricing and access issues, and patent issues. International tax issues and pharmaceutical pricing and access issues, and patent issues.
- 2026-04-20$2.1MABBVIE INC.S.1040, Drug Competition Enhancement Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property S. 864, HELP Copays Act H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act S. 2903, Safe Step Act H.R. 5509, Safe Step Act Drug cost and pricing policy issues Patient affordability issues Issues related to the 340B program Issues related to data privacy Issues related to Hepatitis C elimination Issues related to FDA communications Public Law 117-169 (formerly known as H.R. 5376, Inflation Reduction Act) Implementation regarding Medicare Part D drug negotiation program Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Issues related to HCV treatment H.R. 1328, Supply Chain Security and Growth Act of 2025 H.R. 1990, American Innovation and R&D Competitiveness Act of 2025 Public Law No: 119-
- 2026-04-20$80KABBVIELegislative services related to corporate and international tax matters.
- 2026-04-20$60KABBVIETrade Policy. Patent Legislation. Patent Review Procedures.
- 2026-04-20$60KABBVIE INC.drug pricing in federal programs, transparency, prescription drug pricing and access, beneficiary access, IRA Part B, Part D, drug pricing and access, negotiation, federal budget issues
- 2026-04-20$50KABBVIE INC.Education and legislation related to reform of the 340(b) program. Education around data privacy. Medicare Implementation of the Inflation Reduction Act. Public Law 119-21: One Big Beautiful Bill Act. Issues around drug pricing.
- 2026-04-20$50KABBVIE INC.Patient Access to drug treatment therapies; and drug cost and drug pricing reform. Oversight of the pharmaceutical industry and drug pricing. Policies as they relate to PBMs Issues related to the budget and appropriations process Medicare Part D policies. Monitoring Policies related to the 340b program. Issues related to the implementation of the Inflation Reduction Act Issues related to the budget and appropriations process
- 2026-04-20$30KABBVIE INC.340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain. Prescription drug advertising issues. Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation. Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues. H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.
Loading trade analytics…
All Disclosed Trades
Page 2 · 25 of 141 shown| Date | Member | Action | Amount | Observed Gap | Receipt |
|---|---|---|---|---|---|
| 2025-12-08 | RJulia Letlow | SELL | $1K – $15K | 36d | receipt → |
| 2025-12-08 | RJulia Letlow | SELL | $1K – $15K | 36d | receipt → |
| 2024-10-23 | RJulia Letlow | BUY | $1K – $15K | 447dApparent delay | receipt → |
| 2025-11-13 | DJulie Johnson | SELL | $1K – $15K | 29d | receipt → |
| 2025-11-13 | DJulie Johnson | SELL | $1K – $15K | 28d | receipt → |
| 2025-11-13 | DJulie Johnson | SELL | $1K – $15K | 28d | receipt → |
| 2025-10-30 | RLisa McClain | SELL | $1K – $15K | 25d | receipt → |
| 2025-10-30 | RLisa McClain | BUY | $1K – $15K | 25d | receipt → |
| 2025-10-31 | RLisa McClain | SELL | $1K – $15K | 24d | receipt → |
| 2025-10-31 | RLisa McClain | SELL | $1K – $15K | 21d | receipt → |
| 2025-10-30 | RLisa McClain | SELL | $1K – $15K | 22d | receipt → |
| 2025-10-30 | RLisa McClain | BUY | $1K – $15K | 22d | receipt → |
| 2025-10-31 | RLisa McClain | SELL | $1K – $15K | 21d | receipt → |
| 2025-10-30 | RLisa McClain | SELL | $1K – $15K | 22d | receipt → |
| 2025-10-30 | RLisa McClain | BUY | $1K – $15K | 22d | receipt → |
| 2025-08-11 | RJohn Boozman | PARTIAL_SELL | $1K – $15K | 32d | receipt → |
| 2025-08-14 | DJulie Johnson | SELL | $1K – $15K | 29d | receipt → |
| 2025-08-22 | RJohn Boozman | PARTIAL_SELL | $1K – $15K | 21d | receipt → |
| 2025-08-14 | DJulie Johnson | SELL | $1K – $15K | 28d | receipt → |
| 2025-08-14 | DJulie Johnson | SELL | $1K – $15K | 28d | receipt → |
| 2025-08-04 | DRo Khanna | BUY | $1K – $15K | 36d | receipt → |
| 2025-08-04 | DRo Khanna | BUY | $1K – $15K | 36d | receipt → |
| 2025-07-11 | DRitchie Torres | SELL | $1K – $15K | 41d | receipt → |
| 2025-07-11 | DRitchie Torres | SELL | $1K – $15K | 40d | receipt → |
| 2024-09-26 | DRitchie Torres | BUY | $1K – $15K | 328dApparent delay | receipt → |
“Observed gap” is the calendar distance from transaction date to filing date; only gaps over 45 days receive an apparent-delay marker.